Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,808 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lin G, Wang Z, Chu Q, Hu Y, Huang D, Wang J, Yang F, Zhong W, Zhou C, Zhu B, Ai X, Cao B, Cao Y, Chen M, Chen X, Chu T, Duan J, Fan Y, Fang Y, Feng S, Feng W, Guo H, Han C, He Y, Hong S, Hu J, Huang M, Huang Y, Jiang D, Jiang K, Jiang R, Jin B, Jin S, Li J, Li M, Li Z, Li C, Lin J, Liu A, Liu SM, Yutao L, Liu Z, Liu Z, Liu Z, Liu Z, Liu Z, Lu Y, Lv T, Ma Z, Miao Q, Peng M, Pu X, Ren XB, Shan J, Shan J, Shen P, Shen B, Shi M, Song Y, Song Z, Su C, Sun J, Tian P, Wang J, Wang F, Wang H, Wang J, Wang Q, Wang W, Wang Y, Wu L, Wu F, Xia Y, Xie C, Xie C, Xin T, Xiong J, Xu H, Xu S, Xu Y, Xu B, Xu C, Yan X, Yang Z, Yao W, Yu Y, Feng Y, Yu Z, Yu Y, Yue D, Zhang H, Zhang H, Zhang L, Zhang L, Zhang Q, Zhang T, Zhang B, Zhao J, Zhao M, Zheng X, Zhong Q, Zhou J, Zhou P, Zhu Z, Zou J, Zou Z. Lin G, et al. Among authors: zhou j, zhou p, zhou c. Thorac Cancer. 2024 Feb;15(5):419-426. doi: 10.1111/1759-7714.15209. Epub 2024 Jan 14. Thorac Cancer. 2024. PMID: 38219795 Free PMC article.
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
Song P, Cui X, Bai L, Zhou X, Zhu X, Zhang J, Jin F, Zhao J, Zhou C, Zhou Y, Zhang X, Wang K, Wang Q, Yu Y, Zhang X, Bai C, Zhang L. Song P, et al. Among authors: zhou x, zhou y, zhou c. Thorac Cancer. 2019 May;10(5):1303-1309. doi: 10.1111/1759-7714.13078. Epub 2019 Apr 23. Thorac Cancer. 2019. PMID: 31016875 Free PMC article.
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yang Y, Zhou J, Zhou J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wu N, Song W, Liu X, Zhao S, Ding L, Mao L, Selvaggi G, Yuan X, Fu Y, Wang T, Xiao S, Zhang L. Yang Y, et al. Among authors: zhou j, zhou c. Lancet Respir Med. 2020 Jan;8(1):45-53. doi: 10.1016/S2213-2600(19)30252-8. Epub 2019 Oct 15. Lancet Respir Med. 2020. PMID: 31628085 Clinical Trial.
Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib.
Yuan B, Zhao J, Zhou C, Wang X, Zhu B, Zhuo M, Dong X, Feng J, Yi C, Yang Y, Zhang H, Zhou W, Chen Z, Yang S, Ai X, Chen K, Cui X, Liu D, Shi C, Wu W, Zhang Y, Chang L, Li J, Chen R, Yang S. Yuan B, et al. Among authors: zhou w, zhou c. Front Oncol. 2020 May 12;10:729. doi: 10.3389/fonc.2020.00729. eCollection 2020. Front Oncol. 2020. PMID: 32477948 Free PMC article.
20,808 results
You have reached the last available page of results. Please see the User Guide for more information.